Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. - Wikidata - awgldk - TriplyDB

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

http://www.wikidata.org/entity/Q37431023

about

A murine model for the development of melanocytic nevi and their progression to melanoma.Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma.

P2860

Q36073207-59D8FBC8-9EC6-48D1-A207-544F74F7A33A Q52655061-A9F416DD-443E-4A3C-84E6-E8A238FD3B6A

P2860

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

http://www.wikidata.org/entity/Q37431023

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

@en

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

@nl

type

label

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

@en

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

@nl

prefLabel

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

@en

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

@nl

P1433

Q37431023-45A25946-EBBD-4A8F-8B2A-87075C0ACF47

P1476

Q37431023-DC282579-E11D-4E0C-BFF5-0BC28CC8B492

P2093

Q37431023-011BEF15-55A5-463C-A7F8-DED6AD59D23B

Q37431023-19CBEC09-7AC0-47C8-B7A1-2D9D9F74DD98

Q37431023-35E0C75B-A640-4803-96D8-45E7823C680F

Q37431023-43380BEC-2D81-4B59-829E-D087CA3334EB

Q37431023-861A526E-51F4-4695-9C03-15BD66FD9164

Q37431023-9B59F92B-10C6-4288-BDCA-E1A6F3953CDB

Q37431023-9F803952-AF68-4017-9C06-3B7D707216B6

Q37431023-B562D674-420C-4FE2-AC56-A8E73B23B6F0

Q37431023-BD41FF23-E3A1-4FEE-8060-B8FD92B855BB

Q37431023-C09DF52C-DE8E-4790-A2B6-EE18C4BAFEB4

P2860

Q37431023-1603A538-E110-4D9A-B315-BC40C38074AD

Q37431023-369EA4FA-B672-455A-BF46-999972103A8A

Q37431023-4050A18D-AF45-4028-A040-C4B755BEF447

Q37431023-7D22B658-90B0-4EF4-9CBD-11C8FDA05AD2

Q37431023-7F201A25-67B4-4214-AFDB-2253967A1D93

Q37431023-852A136B-7F71-469A-AF86-BFA8108A0F82

Q37431023-97D2F4B2-DA20-4E98-A494-51A2250F3154

Q37431023-A293AE0C-E75B-4073-8D49-59FC2266CFCD

Q37431023-BB5886FA-438D-425B-AA4D-6B45AADEB085

Q37431023-BC4540F5-85BA-41B2-AB52-223FF8EF6D63

P304

Q37431023-EA42D9B0-60D9-432F-AD8A-F4818EF0C682

P31

Q37431023-70147D52-D5E4-4DD8-9314-62FCE6526A6C

P356

Q37431023-BF8605DE-9508-4B69-B13F-EDB7A77FCABD

P407

Q37431023-D5F7B1C1-2EDE-41C8-9002-4175C261EAD3

P433

Q37431023-95653B54-6D05-41C6-BE1D-E3ECB046BC47

P478

Q37431023-1DB84D43-7FC8-49CA-8967-F7B8EBF3EA78

P577

Q37431023-9C5F4E90-58CE-4F4A-94BA-1A5D6864D605

P698

Q37431023-4E179BAB-41B5-4B8E-ADCB-1C7314867A6A

P932

Q37431023-F6D09BF4-E776-4543-A5DC-3FAB97424B59

P356

CMR.0B013E3283046146

P1433

Melanoma Research

P1476

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

@en

P2093

Abdul H Diwan

http://www.w3.org/2001/XMLSchema#string

Cindy S Hwang

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Grimm

http://www.w3.org/2001/XMLSchema#string

Gregory Lizee

http://www.w3.org/2001/XMLSchema#string

Julie A Ellerhorst

http://www.w3.org/2001/XMLSchema#string

Kevin B Kim

http://www.w3.org/2001/XMLSchema#string

Omar Eton

http://www.w3.org/2001/XMLSchema#string

Patrick Hwu

http://www.w3.org/2001/XMLSchema#string

Ping Liu

http://www.w3.org/2001/XMLSchema#string

Sandra A Kinney

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of STI571 (gleevec) on pancreatic cancer cell growth

Mutations of the BRAF gene in human cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

RKIP downregulates B-Raf kinase activity in melanoma cancer cells

Deregulated Akt3 activity promotes development of malignant melanoma.

Autocrine and paracrine roles for growth factors in melanoma.

Detection of B-RAF and N-RAS mutations in human melanoma.

Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines.

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.

Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression.

P304

241-245

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CMR.0B013E3283046146

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18626307

http://www.w3.org/2001/XMLSchema#string

P932

3880193

http://www.w3.org/2001/XMLSchema#string